{"id":19280,"date":"2026-02-09T17:25:51","date_gmt":"2026-02-09T20:25:51","guid":{"rendered":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\/"},"modified":"2026-02-09T17:25:51","modified_gmt":"2026-02-09T20:25:51","slug":"bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2","status":"publish","type":"ensaio_clinico","link":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/pesquisa\/ensaiosclinicos\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\/","title":{"rendered":"BNT323-01- C\u00e2ncer de Endom\u00e9trio Recidivante \u2013 Express\u00e3o de HER2"},"content":{"rendered":"<div><b data-olk-copy-source=\"MessageBody\">Avaliar a efic\u00e1cia de BNT323 em compara\u00e7\u00e3o \u00e0 quimioterapia escolhida pelo investigador (Paclitaxel ou Doxorrubicina).<\/b><\/div>\n<div aria-hidden=\"true\">&nbsp;<\/div>\n<div><b>Popula\u00e7\u00e3o:<\/b><\/div>\n<ul>\n<li>\u226518 anos;<\/li>\n<li>&nbsp;Ter c\u00e2ncer de endom\u00e9trio confirmado histologicamente que:<\/li>\n<\/ul>\n<ol start=\"1\" data-editing-info=\"{&quot;orderedStyleType&quot;:5}\">\n<li>seja recidivante;<\/li>\n<li>tenha uma pontua\u00e7\u00e3o IHQ 1+, 2+ ou 3+ de HER2, conforme determinado por exames do laborat\u00f3rio central, e<\/li>\n<li>n\u00e3o seja definido como sarcoma verdadeiro.<\/li>\n<\/ol>\n<div><b>Observa\u00e7\u00e3o<\/b>: permite-se carcinossarcoma de \u00fatero.<\/div>\n<ul>\n<li>Ter recebido pelo menos uma linha anterior de terapia \u00e0 base de platina (em qualquer contexto). S\u00e3o permitidas at\u00e9 tr\u00eas linhas;<\/li>\n<li>ECOG 0 a 2;<\/li>\n<\/ul>\n<p>ClinicalTrials.gov:&nbsp;<b>NCT06340568<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Avaliar a efic\u00e1cia de BNT323 em compara\u00e7\u00e3o \u00e0 quimioterapia escolhida pelo investigador (Paclitaxel ou Doxorrubicina). &nbsp; Popula\u00e7\u00e3o: \u226518 anos; &nbsp;Ter c\u00e2ncer de endom\u00e9trio confirmado histologicamente que: seja recidivante; tenha uma pontua\u00e7\u00e3o IHQ 1+, 2+ ou 3+ de HER2, conforme determinado por exames do laborat\u00f3rio central, e n\u00e3o seja definido como sarcoma verdadeiro. Observa\u00e7\u00e3o: permite-se carcinossarcoma [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false},"class_list":["post-19280","ensaio_clinico","type-ensaio_clinico","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BNT323-01- C\u00e2ncer de Endom\u00e9trio Recidivante \u2013 Express\u00e3o de HER2 - IDOR - Instituto D&#039;Or de Pesquisa e Ensino<\/title>\n<link rel=\"canonical\" href=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BNT323-01- C\u00e2ncer de Endom\u00e9trio Recidivante \u2013 Express\u00e3o de HER2 - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta property=\"og:description\" content=\"Avaliar a efic\u00e1cia de BNT323 em compara\u00e7\u00e3o \u00e0 quimioterapia escolhida pelo investigador (Paclitaxel ou Doxorrubicina). &nbsp; Popula\u00e7\u00e3o: \u226518 anos; &nbsp;Ter c\u00e2ncer de endom\u00e9trio confirmado histologicamente que: seja recidivante; tenha uma pontua\u00e7\u00e3o IHQ 1+, 2+ ou 3+ de HER2, conforme determinado por exames do laborat\u00f3rio central, e n\u00e3o seja definido como sarcoma verdadeiro. Observa\u00e7\u00e3o: permite-se carcinossarcoma [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\/\" \/>\n<meta property=\"og:site_name\" content=\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\\\/\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\\\/\",\"name\":\"BNT323-01- C\u00e2ncer de Endom\u00e9trio Recidivante \u2013 Express\u00e3o de HER2 - IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\"},\"datePublished\":\"2026-02-09T20:25:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ensaios Cl\u00ednicos\",\"item\":\"https:\\\/\\\/ptbr.idor.org\\\/pesquisa\\\/ensaiosclinicos\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"BNT323-01- C\u00e2ncer de Endom\u00e9trio Recidivante \u2013 Express\u00e3o de HER2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ptbr.idor.org\\\/#website\",\"url\":\"https:\\\/\\\/ptbr.idor.org\\\/\",\"name\":\"IDOR - Instituto D&#039;Or de Pesquisa e Ensino\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ptbr.idor.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BNT323-01- C\u00e2ncer de Endom\u00e9trio Recidivante \u2013 Express\u00e3o de HER2 - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","canonical":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\/","og_locale":"pt_BR","og_type":"article","og_title":"BNT323-01- C\u00e2ncer de Endom\u00e9trio Recidivante \u2013 Express\u00e3o de HER2 - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","og_description":"Avaliar a efic\u00e1cia de BNT323 em compara\u00e7\u00e3o \u00e0 quimioterapia escolhida pelo investigador (Paclitaxel ou Doxorrubicina). &nbsp; Popula\u00e7\u00e3o: \u226518 anos; &nbsp;Ter c\u00e2ncer de endom\u00e9trio confirmado histologicamente que: seja recidivante; tenha uma pontua\u00e7\u00e3o IHQ 1+, 2+ ou 3+ de HER2, conforme determinado por exames do laborat\u00f3rio central, e n\u00e3o seja definido como sarcoma verdadeiro. Observa\u00e7\u00e3o: permite-se carcinossarcoma [&hellip;]","og_url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\/","og_site_name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\/","url":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\/","name":"BNT323-01- C\u00e2ncer de Endom\u00e9trio Recidivante \u2013 Express\u00e3o de HER2 - IDOR - Instituto D&#039;Or de Pesquisa e Ensino","isPartOf":{"@id":"https:\/\/ptbr.idor.org\/#website"},"datePublished":"2026-02-09T20:25:51+00:00","breadcrumb":{"@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/bnt323-01-cancer-de-endometrio-recidivante-expressao-de-her2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ptbr.idor.org\/"},{"@type":"ListItem","position":2,"name":"Ensaios Cl\u00ednicos","item":"https:\/\/ptbr.idor.org\/pesquisa\/ensaiosclinicos\/"},{"@type":"ListItem","position":3,"name":"BNT323-01- C\u00e2ncer de Endom\u00e9trio Recidivante \u2013 Express\u00e3o de HER2"}]},{"@type":"WebSite","@id":"https:\/\/ptbr.idor.org\/#website","url":"https:\/\/ptbr.idor.org\/","name":"IDOR - Instituto D&#039;Or de Pesquisa e Ensino","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ptbr.idor.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_links":{"self":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico\/19280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/ensaio_clinico"}],"about":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/types\/ensaio_clinico"}],"wp:attachment":[{"href":"https:\/\/www.rededorsaoluiz.com.br\/instituto\/idor\/wp-json\/wp\/v2\/media?parent=19280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}